access to new medicine

Avril 12, 2023 1:00AM

Waiting for New Medicines: How Does Canada Compare to the United States and Europe?

Étiquettes:

Mai 13, 2021 1:00AM

Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union

Bacchus Barua, Will Westcott, Van Nghiem Vo

Étiquettes:

access to medicines, access to new drugs, access to new medicine, new prescription drugs, new drug approval, new drug regulations, new drugs, pharmaceutical

Octobre 29, 2020 12:02PM

Mandatory switching of biologic drugs—beware of potential side-effects

Yanick Labrie

Last year, British Columbia became the first province to introduce a mandatory biosimilar switching program for non-medical reasons.

Étiquettes:

biologic medicine, biosimilars, access to new drugs, access to new medicine

Juillet 9, 2020 1:00AM

Biologics and Biosimilars: A Primer

Kristina M.L. Acri, née Lybecker

Étiquettes:

biologics, biologic medicine, biosimilars, generic drugs, access to new medicine, pharmaceutical innovation, biotechnology

Avril 15, 2020 11:26AM

Trade deal will hurt—not help—COVID vaccine mission

Kristina M.L. Acri, née Lybecker

The biopharmaceutical industry is uniquely prepared to combat COVID-19.

Étiquettes:

trade deals, USMCA, COVID, medical innovations, access to new medicine

Juillet 11, 2019 1:00AM

Universal Insurance for Pharmaceuticals in Switzerland and the Netherlands

Kristina M.L. Acri, née Lybecker, Bacchus Barua

Étiquettes:

pharmacare, fair pharmacare, access to medicines, access to new medicine, national drug plan, universal drug program, universal health insurance, prescription drug prices

Mars 18, 2019 3:03PM

Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

Dr. Nigel Rawson, Bacchus Barua

Unfortunately, the federal government’s track record of creating reliable and accurate data systems is not good.

Étiquettes:

pharmacare, access to new drugs, access to new medicine, pharmaceutical drugs, pharmaceutical regulations

Février 21, 2019 10:03AM

Trudeau government's drug-pricing plan may limit access to new life-improving medicines

Bacchus Barua, Steven Globerman

Developing and testing new drugs costs a lot of money.

Étiquettes:

drug price controls, access to new drugs, access to new medicine, new prescription drugs, new drug regulations

Janvier 24, 2019 1:00AM

Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective

Steven Globerman, Bacchus Barua

Étiquettes:

pharmaceutical regulations, access to new drugs, pharmaceutical innovation, pmprb, access to new medicine, reference pricing

Novembre 1, 2018 11:01AM

When pharmaceutical innovators take risks, we end up with new drugs that lengthen our lives

Yanick Labrie, Vincent Geloso

Nobel laureate Paul Romer’s key new insight was that human capital can produce ideas.

Étiquettes:

intellectual property, pharmaceuticals, access to new medicine, patients, new prescription drugs

Formulaire de recherche

access to new medicine

Waiting for New Medicines: How Does Canada Compare to the United States and Europe?

Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union

Mandatory switching of biologic drugs—beware of potential side-effects

Biologics and Biosimilars: A Primer

Trade deal will hurt—not help—COVID vaccine mission

Universal Insurance for Pharmaceuticals in Switzerland and the Netherlands

Trudeau government advisors prescribe vast bureaucracy to manage national pharmacare

Trudeau government's drug-pricing plan may limit access to new life-improving medicines

Pharmaceutical Regulation, Innovation, and Access to New Drugs: An International Perspective

When pharmaceutical innovators take risks, we end up with new drugs that lengthen our lives